Welcome to our dedicated page for Aspen Aerogels SEC filings (Ticker: ASPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspen Aerogels Inc. (ASPN) files regular SEC disclosures documenting its operations as a specialty materials manufacturer serving industrial energy, LNG, and construction insulation markets. The company's 10-K annual reports detail revenue breakdown across customer segments and geographic markets, manufacturing capacity utilization, inventory levels of aerogel products, and research and development spending on materials science and production processes. For a company commercializing advanced materials technology, these annual filings reveal critical metrics including production yield rates, customer concentration risks, and the relationship between manufacturing scale and unit economics.
Quarterly 10-Q filings track Aspen Aerogels' revenue trends across its industrial and commercial markets, working capital requirements for inventory and receivables, and capital expenditures for manufacturing expansion. The company's filings disclose backlog levels, significant customer contracts, and supply chain arrangements for raw materials used in aerogel production. These reports provide visibility into the company's progress commercializing aerogel technology and expanding market penetration beyond initial industrial applications.
Material events appear in 8-K filings, including announcements of significant customer agreements, credit facility amendments, manufacturing facility expansions, and strategic partnerships. For a growth-stage specialty materials company, these disclosures often signal important business developments such as capacity additions, market entry into new applications, or financing activities to support expansion. Executive transactions filed on Form 4 show insider buying and selling activity, providing insight into management's perspective on company valuation and business prospects.
Access Aspen Aerogels' complete SEC filing history to analyze the company's financial trajectory, manufacturing scale-up progress, and market development efforts in the specialty insulation sector. Our platform provides real-time updates from EDGAR with AI-powered summaries explaining key disclosures in quarterly and annual reports.
Aspen Aerogels filed an amended insider ownership report for its CFO and Treasurer following an equity grant. On October 1, 2025, the officer acquired 10,273 restricted stock units (RSUs) of common stock at a price of $0 per unit, reflecting a compensation award rather than an open-market purchase.
Each RSU represents one share of common stock and vests in three equal installments: one-third on March 5, 2026, one-third on March 5, 2027, and the final third on March 5, 2028. After correcting prior figures, the filing states the officer beneficially owns 25,392 share-based interests, consisting of 4,608 shares of common stock and 20,784 RSUs. The amendment explains that an earlier report had omitted 10,511 RSUs that were granted before the October 1, 2025 transaction date.
Aspen Aerogels filed an amended insider ownership report for its CFO and Treasurer. The filing shows that the officer beneficially owns 15,119 shares of common stock, including 4,608 shares of common stock and 10,511 restricted stock units (RSUs). The RSUs were granted on March 8, 2023, March 5, 2024, and March 5, 2025, with various time-based vesting schedules extending through March 5, 2028. The amendment clarifies that these unvested RSUs had been inadvertently omitted from the reporting person’s original filing.
Aspen Aerogels, Inc. disclosed that on
The changes also clarify that mandatory prepayments from asset sale proceeds will reduce scheduled amortization payments in direct order of maturity and reduce the basket for permitted acquisitions under the facility. Aspen Aerogels furnished a press release describing the amendment as an exhibit to this report.
Aspen Aerogels (ASPN) reported an insider transaction by its President and CEO (also a Director). On 11/13/2025, the reporting person sold 56,845 shares of common stock (Transaction Code S) under a pre‑arranged Rule 10b5‑1 trading plan. The plan was adopted on August 11, 2025 to sell a limited number of shares for tax purposes related to a one-time personal real estate transaction.
The sale price reflected a weighted average of $3.23, with trades executed between $3.15 and $3.41. Following the transaction, the reporting person beneficially owns 494,011 equity units, comprising 414,306 shares of common stock and 79,705 restricted stock units. Ownership is reported as Direct (D). The filing includes Exhibit 24.1 (Power of Attorney) and was signed by Attorney‑in‑Fact Glenn Deegan on 11/14/2025.
ASPN filed a Form 144 notice for a proposed sale of 56,845 shares of Common stock through Morgan Stanley Smith Barney LLC, listing an aggregate market value of $194,978.35. The filing lists an approximate sale date of November 13, 2025 on the NYSE.
The shares were acquired on May 28, 2024 via previously exercised stock options from the issuer, with payment made in cash on the same date. Shares outstanding were 82,647,081; this is a baseline figure, not the amount being sold.
Aspen Aerogels (ASPN) filed its Q3 2025 10‑Q, showing a sharp year-over-year contraction. Q3 revenue was $73,017, down from $117,340, with gross profit of $20,799 versus $49,043. The quarter swung to an operating loss of $3,348 and a net loss of $6,334.
For the nine months, revenue was $229,764 versus $329,611 last year, and net loss reached $316,639, primarily due to a $287,567 impairment tied to ceasing construction of the Statesboro, Georgia plant. Total assets fell to $491,395 from $895,144 at year-end, while stockholders’ equity declined to $305,733.
Cash and cash equivalents were $150,722. Debt included a term loan of $99,000 and a revolving balance of $14,252; availability under the revolver was $26.8 million. Two customers represented 72% of year-to-date revenue, and one customer accounted for 69% of accounts receivable. Management states it is in compliance with amended MidCap covenants as of September 30, 2025, but notes no assurance of compliance at the end of Q4 2025.
Aspen Aerogels, Inc. (ASPN) furnished an update on its business by announcing financial results for the third quarter of 2025, for the period ended September 30, 2025. The company attached a detailed press release as Exhibit 99.1.
Information about results is furnished under Item 2.02, while “2025 Financial Outlook” and company background are furnished under Item 7.01. The materials are being furnished, not filed, under the Exchange Act.
Grant Douglas Thoele, CFO & Treasurer of Aspen Aerogels, reported changes in beneficial ownership on 10/01/2025. He was granted 10,273 restricted stock units (RSUs) that convert to one share each upon vesting and now beneficially owns 14,881 shares (comprised of 4,608 currently held shares plus the 10,273 RSUs). He also received 14,563 stock options with a $7.30 exercise price exercisable through 10/01/2035, and 20,547 performance share units (PSUs) that vest after the performance period ending 12/31/2027 and may pay out between 0–200% of target based on Aspen’s total shareholder return versus the Russell 2000. The RSUs and options vest in three equal annual tranches beginning 3/5/2026. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Glenn E. Deegan, Chief Administrative Officer, General Counsel and Corporate Secretary of Aspen Aerogels, Inc. (ASPN), reported equity awards granted on 09/30/2025. The filing shows 11,673 RSUs, 16,416 stock options with a $6.96 exercise price and a 09/30/2035 expiration, and 23,347 performance share units (PSUs). The RSUs and options each vest in three equal annual tranches on 09/30/2026, 09/30/2027 and 09/30/2028. The PSUs vest on 03/05/2028 following a performance period from 01/01/2025 to 12/31/2027, and payout ranges from 0% to 200% of target based on total shareholder return relative to the Russell 2000 components. The reported beneficial ownership counts after the transactions are 11,673 RSUs, 16,416 options, and 23,347 PSUs.
Aspen Aerogels reporting person Grant Thoele filed an initial Form 3 disclosing his beneficial ownership in ASPN. He directly holds 4,608 shares of common stock and holds multiple stock option grants exercisable between 11/02/2031 and 03/05/2035 covering a total of several thousand shares at exercise prices from $7.84 to $52.60. He also holds 12,755 performance share units that vest after a performance period ending 12/31/2027 and pay out based on relative total shareholder return versus the Russell 2000.
FAQ
What is the current stock price of Aspen Aerogels (ASPN)?
What is the market cap of Aspen Aerogels (ASPN)?
